[18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
[18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis ; volume:16 ; number:1 ; day:28 ; month:1 ; year:2021 ; pages:1-5 ; date:12.2021
Orphanet journal of rare diseases ; 16, Heft 1 (28.1.2021), 1-5, 12.2021
- Urheber
-
Gallais Sérézal, I.
Ferkal, S.
Lerman, L.
Mulé, S.
Funalot, B.
Wolkenstein, P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-021-01680-0
- URN
-
urn:nbn:de:101:1-2021032120211426255297
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gallais Sérézal, I.
- Ferkal, S.
- Lerman, L.
- Mulé, S.
- Funalot, B.
- Wolkenstein, P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals
18F-FDG positron emission tomography/computed tomography of cardiac implantable electronic device infections
Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice
Role of 18F-FDG positron emission tomography in carotid atherosclerotic plaque imaging: A systematic review
18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study
Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography
In vivo molecular imaging of experimental joint inflammation by combined 18F-FDG positron emission tomography and computed tomography
Added value of regional 18F-FDG PET/MRI-assisted whole-body 18F-FDG PET/CT in malignant ascites with unknown primary origin
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation
Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies
Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals
18F-FDG positron emission tomography/computed tomography of cardiac implantable electronic device infections
Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice
Role of 18F-FDG positron emission tomography in carotid atherosclerotic plaque imaging: A systematic review
18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study
Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography
In vivo molecular imaging of experimental joint inflammation by combined 18F-FDG positron emission tomography and computed tomography
Added value of regional 18F-FDG PET/MRI-assisted whole-body 18F-FDG PET/CT in malignant ascites with unknown primary origin
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation
Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies
Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals
18F-FDG positron emission tomography/computed tomography of cardiac implantable electronic device infections
Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice
Role of 18F-FDG positron emission tomography in carotid atherosclerotic plaque imaging: A systematic review
18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study
Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography
In vivo molecular imaging of experimental joint inflammation by combined 18F-FDG positron emission tomography and computed tomography
Added value of regional 18F-FDG PET/MRI-assisted whole-body 18F-FDG PET/CT in malignant ascites with unknown primary origin
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation